Cargando…
Management of Myeloma Bone Lesions
Multiple myeloma (MM) is a B-cell neoplasm characterized by clonal plasma–cell proliferation. The survival and prognosis of this condition have been significantly improved by treatment with active anti-MM drugs such as bortezomib or lenalidomide. Further, the discovery of novel agents has recently p...
Autores principales: | Du, Jeng-Shiun, Yen, Chia-Hung, Hsu, Chin-Mu, Hsiao, Hui-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036461/ https://www.ncbi.nlm.nih.gov/pubmed/33806209 http://dx.doi.org/10.3390/ijms22073389 |
Ejemplares similares
-
Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2
por: Yen, Chia-Hung, et al.
Publicado: (2020) -
Pathogenesis and Treatment of Myeloma-Related Bone Disease
por: Gau, Yuh-Ching, et al.
Publicado: (2022) -
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
por: Yen, Chia-Hung, et al.
Publicado: (2018) -
Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy
por: Hsu, Chin-Mu, et al.
Publicado: (2022) -
Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment
por: Tsai, Yu-Fen, et al.
Publicado: (2021)